Erlotinib in Lung Cancer [1] (multiple letters)

New England Journal of Medicine

Volumn 353, Issue 16, 2005, Pages 1739-1741

  Nabhan, Chadi ^a   Bitran, Jacob D ^a   Takano, Toshimi ^b   Ohe, Yuichiro ^b   Pao, William ^c   Ladanyi, Marc ^c   Miller, Vincent A ^c   Shepherd, Frances A ^d   Seymour, Lesley ^e   Tsao, Ming Sound ^d   Kamel Reid, Suzanne ^d  

^a Lutheran General Cancer Center   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e Clinical Trials Group   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; PEMETREXED; PLACEBO; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; GEFITINIB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; ETHICS; LUNG TUMOR; NOTE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; GENETICS; MUTATION; POLYMERASE CHAIN REACTION; MORTALITY; NUCLEOTIDE SEQUENCE; STANDARD; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLACEBOS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; MUTATION; POLYMERASE CHAIN REACTION; DNA MUTATIONAL ANALYSIS; SURVIVAL ANALYSIS;

EID: 26844465534     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc052173     Document Type: Letter

References (0)